Keshelava Nino, Frgala Tomás, Krejsa Jirí, Kalous Ondrej, Reynolds C Patrick
USC-CHLA Institute for Pediatric Clinical Research, University of Southern California and Childrens Hospital Los angeles, Los Angeles, CA, USA.
Methods Mol Med. 2005;110:139-53. doi: 10.1385/1-59259-869-2:139.
DIMSCAN is a semiautomatic fluorescence-based digital image microscopy system that quantifies relative total (using a DNA stain) or viable (using fluorescein diacetate [FDA]) cell numbers in tissue culture multiwell plates ranging from 6 to 384 wells per plate. DIMSCAN is a rapid and efficient tool for conducting in vitro cytotoxicity assays across a 4 log dynamic range. The specificity of detecting viable cells with FDA is achieved by using digital image processing and chemical quenching of fluorescence in nonviable cells with eosin Y. Average scan time for the most commonly used format, a 96-well plate, is 6 min. Cytotoxicity for neuroblastoma cell lines measured by DIMSCAN was found to be comparable to manual Trypan blue dye exclusion counts or colony formation in soft agar, but with a significantly wider dynamic range, which enables drug combination studies used to detect synergistic or antagonistic interactions. The linearity of DIMSCAN was validated (r2 = 0.99967 +/- 0.0003) for cells stained with FDA deposited using a fluorescence-activated cell sorter, documenting a dynamic range > 4 logs, and the ability to detect a single viable cell in a well 93% of the time. DIMSCAN has been used to demonstrate preclinical activity of cytotostatic and cytotoxic drugs and drug combinations that have subsequently shown activity in clinical trials.
DIMSCAN是一种基于荧光的半自动数字图像显微镜系统,可对组织培养多孔板(每板6至384孔)中的相对总细胞数(使用DNA染色)或活细胞数(使用荧光素二乙酸酯[FDA])进行定量。DIMSCAN是一种快速有效的工具,可在4个对数动态范围内进行体外细胞毒性测定。通过使用数字图像处理和用曙红Y对非活细胞中的荧光进行化学淬灭,实现了用FDA检测活细胞的特异性。最常用的96孔板格式的平均扫描时间为6分钟。发现通过DIMSCAN测量的神经母细胞瘤细胞系的细胞毒性与手动台盼蓝染料排除计数或软琼脂中的集落形成相当,但动态范围明显更宽,这使得药物联合研究能够用于检测协同或拮抗相互作用。对于使用荧光激活细胞分选仪沉积的用FDA染色的细胞,DIMSCAN的线性得到了验证(r2 = 0.99967 +/- 0.0003),记录了动态范围> 4个对数,并且能够在93%的时间内检测到孔中的单个活细胞。DIMSCAN已被用于证明随后在临床试验中显示出活性的细胞抑制和细胞毒性药物及药物组合的临床前活性。